News | January 28, 2022
Lupin signs promotional agreement with Exeltis on SOLOSEC
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
The covid health center will be managed and administered by the district administration of Ballari
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Previously, the use of the drug was limited to patients requiring hospitalization
Subscribe To Our Newsletter & Stay Updated
